The goal of this interventional clinical study is to learn if a Tinder fungus-based formulation -specifically a toothpaste and oral supplement powder-works as adjuncts to non-surgical periodontal therapy (NSPT) in patients with periodontitis.
The main questions it aims to answer is:
• Does the Tinder fungus-based formulation as an adjunct to NSPT reduce bleeding on probing more than a commercially available toothpaste as an adjunct to NSPT? Researchers will compare tinder fungus toothpaste and oral powder as an adjunct to NSPT to a commercially available toothpaste as an adjunct to NSPT to see if the Tinder fungus-based formulation works as adjuncts to NSPT in patients with periodontitis.
Participants will:
* Take tinder fungus toothpaste and oral powder or a commercially available toothpaste as an adjunct to NSPT twice daily for 30 consecutive days * Visit the clinic at least twice including a visit before and after the intervention * Keep a diary documenting their well-being and the number of times they used the toothpastes in the morning and evening.
Patients diagnosed with Stage III or IV periodontitis
Patients who have not yet initiated periodontal therapy
Patients who have at least 20 remaining teeth
Patients who are willing to use an electric toothbrush
Patients who have previously received treatment for periodontitis
Patients who have already undergone or initiated periodontal therapy
Patients with a known allergy or intolerance to any component of the toothpaste or the powder
Patients who are already using a product that contains tinder fungus (Fomes fomentarius)
Parallel
Tinder fungus-based formulation
Other interventionParticipants will receive Tinder fungus (Fomes fomentarius)-based formulations including a toothpaste plus an oral supplement powder as adjuncts to non-surgical periodontal therapy (NSPT).
Commercially available toothpaste
Other interventionA standard commercially available toothpaste administered as an adjunct to NSPT.
Bleeding on probing (BoP in %) change
Bleeding on probing (BoP in %) changes from baseline (T0) to reevaluation (T1). BOP will be recorded as yes/no for each of 6 sites and reported as the percentage of affected sites per participant.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
